钠-葡萄糖协同转运蛋白2抑制剂肾脏保护作用的研究进展

doi:10.3969/j.issn.1004-583X.2022.05.016

摘要/Abstract

摘要：

钠-葡萄糖协同转运蛋白2抑制剂(sodium-dependent glucose transporters 2 inhibition,SGLT2i)是一种新型降糖药,以近端肾小管的钠-葡萄糖协同转运蛋白2(sodium-dependent glucose transporters 2,SGLT2)为作用靶点,上市初期以降糖为主要目的。既往有关SGLT2i对糖尿病患者心肾保护作用的研究发现,该药除具有不依赖胰岛素降糖的独特作用外,且对无论是否患有2型糖尿病的慢性肾脏病(chronic kidney disease,CKD)患者均具有肾脏保护作用。本文通过汇总近年来SGLT2i肾脏保护的相关临床研究并对SGLT2i肾脏保护的潜在机制进行综述,旨在为未来SGLT2i可能在非糖尿病肾病患者中的应用提供一定的理论依据。

中图分类号:

R587.24

程霞, 程兰兰, 张鹏伟, 马志刚. 钠-葡萄糖协同转运蛋白2抑制剂肾脏保护作用的研究进展[J]. 临床荟萃, 2022, 37(5): 467-471.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.05.016

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I5/467

参考文献 39

[1]	GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the global burden of disease study 2017[J]. Lancet, 2020, 395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3 URL
[2]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: A cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. doi: 10.1016/S0140-6736(12)60033-6 URL
[3]	Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease[J]. J Intern Med, 2007, 261(1):32-43. doi: 10.1111/j.1365-2796.2006.01746.x pmid: 17222166
[4]	Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: An emerging new class of oral antidiabetic drug[J]. Diabetes Obes Metab, 2009, 11(2):79-88. doi: 10.1111/j.1463-1326.2008.00982.x URL
[5]	Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2[J]. Diabetologia, 2018, 61(10): 2087-2097. doi: 10.1007/s00125-018-4656-5 URL
[6]	Leoncini G, Russo E, Bussalino E, et al. SGLT2is and renal protection: From biological mechanisms to real-world clinical benefits[J]. Int J Mol Sci, 2021, 22(9):4441. doi: 10.3390/ijms22094441 URL
[7]	Ellison DH. SGLT2 inhibitors, hemodynamics, and kidney protection[J]. Am J Physiol Renal Physiol, 2021, 321(1):F47-F49. doi: 10.1152/ajprenal.00092.2021 URL
[8]	Mittal N, Sehray V, Mittal R, et al. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data[J]. Eur J Pharmacol, 2021, 907:174320. doi: 10.1016/j.ejphar.2021.174320 URL
[9]	Wintrich J, Abdin A, Böhm M. Management strategies in heart failure with preserved ejection fraction[J]. Herz, 2022:1-8.
[10]	Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15):1413-1424. doi: 10.1056/NEJMoa2022190 URL
[11]	Palmiero G, Cesaro A, Vetrano E, et al. Impact of SGLT2 inhibitors on heart failure: From pathophysiology to clinical effects[J]. Int J Mol Sci, 2021, 22(11):5863. doi: 10.3390/ijms22115863 URL
[12]	Yanai H, Hakoshima M, Adachi H, et al. Multi-organ protective effects of sodium glucose cotransporter 2 inhibitors[J]. Int J Mol Sci, 2021, 22(9):4416. doi: 10.3390/ijms22094416 URL
[13]	Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials[J]. Lancet, 2020, 396(10254):819-829. doi: S0140-6736(20)31824-9 pmid: 32877652
[14]	Rhee JJ, Jardine MJ, Chertow GM, et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY[J]. Diabetes Obes Metab, 2020, 22(Suppl 1):46-54. doi: 10.1111/dom.13987 URL
[15]	Patel AB, Mistry K, Verma A. DAPA-CKD: Significant victory for CKD with or without diabetes[J]. Trends Endocrinol Metab, 2021, 32(6):335-337. doi: 10.1016/j.tem.2021.02.007 URL
[16]	McMurray JJV, Wheeler DC, Stefánsson BV, et al. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease[J]. Circulation, 2021, 143(5):438-448. doi: 10.1161/CIRCULATIONAHA.120.051675 pmid: 33186054
[17]	Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15):1436-1446. doi: 10.1056/NEJMoa2024816 URL
[18]	McQuarrie EP, Gillis KA, Mark PB. Seven suggestions for successful SGLT2i use in glomerular disease-a standalone CKD therapy?[J]. Curr Opin Nephrol Hypertens, 2022, 31(3):272-277. doi: 10.1097/MNH.0000000000000786 URL
[19]	Heerspink HJL, Sjöström CD, Jongs N, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial[J]. Eur Heart J, 2021, 42(13):1216-1227. doi: 10.1093/eurheartj/ehab094 pmid: 33792669
[20]	Lin FJ, Wang CC, Hsu CN, et al. Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: A multi-center study[J]. Cardiovasc Diabetol, 2021, 20(1):203. doi: 10.1186/s12933-021-01396-2 URL
[21]	Cherney DZI, Dekkers CCJ, Barbour SJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial[J]. Lancet Diabetes Endocrinol, 2020, 8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5 URL
[22]	Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(21):2098-2099.
[23]	Xie Y, Bowe B, Gibson AK, et al. Clinical implications of estimated glomerular filtration rate dip following sodium-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes[J]. J Am Heart Assoc, 2021, 10(11):e020237. doi: 10.1161/JAHA.120.020237 URL
[24]	孔淑君, 陈卫东. 慢性肾脏病氧化应激的研究进展[J]. 国际泌尿系统杂志, 2020(4):759-762.
[25]	Almaimani M, Sridhar VS, Cherney DZI. Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease[J]. Curr Opin Nephrol Hypertens, 2021, 30(5):474-481. doi: 10.1097/MNH.0000000000000724 URL
[26]	Kale A, Sankrityayan H, Anders HJ, et al. Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes[J]. Drug Discov Today, 2021, 26(8):1963-1971. doi: 10.1016/j.drudis.2021.04.007 URL
[27]	Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition[J]. Cell Metab, 2020, 32(3):404-419.e6. doi: S1550-4131(20)30358-2 pmid: 32726607
[28]	张启伦, 叶山东. SGLT2抑制剂肾脏外糖代谢调控机制的研究进展[J]. 国际内分泌代谢杂志, 2021, 41(4):360-363.
[29]	张瀚桢, 郝传明. 钠-葡萄糖共转运蛋白2抑制剂在非糖尿病肾脏疾病中的肾脏保护机制研究进展[J]. 中华肾脏病杂志, 2022, 38(4):359-363. doi: 10.3760/cma.j.cn441217-20211210-00052
[30]	Hasan R, Lasker S, Hasan A, et al. Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress mode[J]. Sci Rep, 2020, 10(1):14659. doi: 10.1038/s41598-020-71599-2 URL
[31]	Lu YH, Chang YP, Li T, et al. Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK/AKT/CREB signaling pathway in type 2 diabetic mice[J]. Int J Biol Sci, 2020, 16(3):529-542. doi: 10.7150/ijbs.33007 URL
[32]	Bao L, Gao X, Xie K, et al. Is there a diabetes-kidney-heart continuum? Perspectives from the results of the cardiovascular and renal outcome clinical trials with SGLT2 inhibitors[J]. Front Cardiovasc Med, 2021, 8:716083. doi: 10.3389/fcvm.2021.716083 URL
[33]	Dekkers CCJ, Gansevoort RT. Sodium-glucose cotransporter 2 inhibitors: Extending the indication to non-diabetic kidney disease?[J]. Nephrol Dial Transplant, 2020, 35(Suppl 1):i33-i42. doi: 10.1093/ndt/gfz264 URL
[34]	Reyes-Pardo H, Bautista R, Vargas-Robles H, et al. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage[J]. BMC Nephrol, 2019, 20(1):292. doi: 10.1186/s12882-019-1490-z pmid: 31375080
[35]	Nespoux J, Patel R, Zhang H, et al. Gene knockout of the Na⁺-glucose cotransporter SGLT2 in a murine model of acute kidney injury induced by ischemia-reperfusion[J]. Am J Physiol Renal Physiol, 2020, 318(5):F1100-F1112. doi: 10.1152/ajprenal.00607.2019 URL
[36]	Novikov A, Fu Y, Huang W, et al. SGLT2 inhibition and renal urate excretion: Role of luminal glucose, GLUT9, and URAT1[J]. Am J Physiol Renal Physiol, 2019, 316(1):F173-F185. doi: 10.1152/ajprenal.00462.2018 URL
[37]	王燕磊, 肖建中. 钠-葡萄糖共转运蛋白2抑制剂的肾脏保护循证证据与潜在机制[J]. 中华糖尿病杂志, 2021(10):1008-1012.
[38]	刘玲, 张玲. 血脂异常与慢性肾脏疾病[J]. 国际泌尿系统杂志, 2007(5):680-682.
[39]	Xu J, Kitada M, Ogura Y, et al. Dapagliflozin restores impaired autophagy and suppresses inflammation in high glucose-treated HK-2 cells[J]. Cells, 2021, 10(6):1457. doi: 10.3390/cells10061457 URL

钠-葡萄糖协同转运蛋白2抑制剂肾脏保护作用的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨星梦, 马晓迎, 生玉平, 刘烨, 张浩然, 徐海平, 王娜, 孙福云. 慢性肾脏病5期非透析患者同型半胱氨酸与腹主动脉钙化的相关性[J]. 临床荟萃, 2024, 39(1): 30-33.
[2]	陈婷, 刘金彦. 中药靶向PI3K/Akt/mTOR通路调节自噬在糖尿病肾脏病中的研究进展[J]. 临床荟萃, 2023, 38(6): 564-568.
[3]	李会芳, 苗霞. 甲状腺激素水平对2型糖尿病肾脏病风险的预测[J]. 临床荟萃, 2023, 38(2): 137-142.
[4]	刘亚鑫, 郭岚, 王泽凯, 牛凯. 慢性肾脏病合并骨质疏松症治疗的研究进展[J]. 临床荟萃, 2023, 38(12): 1146-1149.
[5]	王翠, 林昊, 武萍萍, 张雅丽, 任建, 徐婷, 董国玉, 宰国田. 2型糖尿病患者高同型半胱氨酸血症与早期肾脏疾病的相关性[J]. 临床荟萃, 2023, 38(1): 42-45.
[6]	姚瑶, 褚敏. 糖尿病肾病患者认知功能障碍与血清β淀粉样蛋白的关系[J]. 临床荟萃, 2022, 37(9): 813-816.
[7]	高士欣, 宋冰, 施克新. 血清脂蛋白α、胱抑素-C和尿酸检测对早期糖尿病肾病的诊断价值[J]. 临床荟萃, 2022, 37(3): 248-252.
[8]	杜菲, 李英. 老年糖尿病肾病患者肠道菌群失调的研究进展[J]. 临床荟萃, 2022, 37(2): 178-181.
[9]	邱建美, 王德峰. 恩格列净治疗2型糖尿病的研究现状[J]. 临床荟萃, 2022, 37(2): 170-173.
[10]	贺枫, 牛璐, 雒杲, 杨睿斐, 李凡凡, 成晓琼, 安斌斌, 李京娟, 刘媛媛, 郭茜, 王金羊. 中国人内脏脂肪指数及内脏脂肪面积与糖尿病肾病的相关性及其预警价值[J]. 临床荟萃, 2022, 37(12): 1089-1093.
[11]	刘猛, 胡桂才, 杨宗娜, 郭伟伟, 陈万欣. 糖尿病肾脏疾病与非糖尿病肾脏疾病血液透析患者容量负荷与营养状况的比较[J]. 临床荟萃, 2021, 36(4): 332-335.
[12]	刘伦志, 邓璐, 张明霞. 血管紧张素Ⅱ1型受体拮抗剂对早期糖尿病肾病患者尿液中足细胞相关蛋白nephrin、自噬基因Beclin-1 mRNA排泄的影响[J]. 临床荟萃, 2021, 36(11): 1005-1008.
[13]	沈琰, 黄诗纯, 陈怡, 詹明. 焦虑和抑郁心理状态对糖尿病肾病影响的研究进展[J]. 临床荟萃, 2021, 36(11): 1029-1033.
[14]	武肖珊, 李英. 钠-葡萄糖协同转运蛋白2抑制剂对糖尿病肾病保护作用的研究进展[J]. 临床荟萃, 2021, 36(11): 1034-1040.
[15]	王亚丽, 王瑞英, 崔月. 2型糖尿病患者尿白蛋白与葡萄糖负荷后2小时血糖增值的关系[J]. 临床荟萃, 2021, 36(1): 49-53.